Loading...
•
Sep 30, 2024
Pacira Q3 2024 Earnings Report
Pacira BioSciences reported solid sales in the third quarter, driven by progress in clinical pipeline and commercial portfolio.
Key Takeaways
Pacira BioSciences reported third quarter 2024 financial results with total revenues of $168.6 million. Net loss was $143.5 million, or $3.11 per share. Adjusted EBITDA was $54.7 million. The company is reiterating its full-year 2024 financial guidance.
Total revenues were $168.6 million.
EXPAREL net product sales were $132.0 million.
Net loss was $143.5 million, or $3.11 per share (basic and diluted).
Adjusted EBITDA was $54.7 million.
Revenue by Segment
Forward Guidance
The company is reiterating its full-year 2024 financial guidance as follows:
Positive Outlook
- Total revenue of $680 million to $705 million
- Non-GAAP gross margin of 74% to 76%
- Non-GAAP R&D expense of $70 million to $80 million
- Non-GAAP SG&A expense of $245 million to $265 million
- Stock-based compensation of $50 million to $55 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...